Shennon Biotechnologies

Market position

Shennon positions its approach against conventional discovery workflows that test candidate binders sequentially over months, arguing that parallel single-cell functional screening and an integrated discovery engine allow faster iteration and more selective, safer therapeutics.

Differentiation claims center on massively parallel functional screening at the single-cell level rather than sequential binder testing, integration of target discovery, screening, computational optimization and predictive safety assessment into one workflow rather than discrete steps, proprietary human tumor datasets from a 15-institution collaborator network, and the ability to address intracellular as well as surface cancer targets.

Technology

The core technology is the TCELERATOR platform, a single-cell functional screening system capable of profiling more than 10 million single-cell interactions at once to identify functional leads in one experiment. This is integrated with computational engineering, including computational optimization of binders, and translational immunology, together with predictive safety assessment, into a single discovery workflow. The company applies the platform to develop T-cell engagers against both surface and intracellular cancer targets, and its datasets derive from human tumor samples supplied by academic and clinical collaborators.

Go-to-market

The company's stated therapeutic focus is solid tumor cancers, and it works with academic and clinical collaborators across 15 institutions that contribute to its proprietary human tumor datasets. It also invites partnering inquiries.

Geography

Headquartered at 2325 3rd Street, San Francisco, CA, with 6,000 square feet of laboratory and office space near UCSF Mission Bay; all listed job openings are in San Francisco.

History

Shennon Biotechnologies emerged from stealth in March 2023, announcing a $13 million seed financing to accelerate immunotherapy target discovery using its proprietary single-cell functional screening platform. It has since built out an interdisciplinary team spanning platform engineering, computational biology, protein science and immunology, alongside a scientific and business advisory board, and is recruiting for roles including CSO / VP of R&D.